Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lyra Therapeutics Inc LYRA

Healthcare
Lyra Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). The Company has two investigational product candidates, LYR-210 and LYR-220, in late-stage development for CRS, a prevalent inflammatory disease of the paranasal sinuses that... see more

Recent & Breaking News (NDAQ:LYRA)

Lyra Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

GlobeNewswire March 29, 2023

Lyra Therapeutics Announces Appointment of John Bishop, Ph.D., as Chief Technology Officer

GlobeNewswire February 27, 2023

Lyra Therapeutics Announces Completion of Enrollment in the BEACON Phase 2 Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients

GlobeNewswire February 6, 2023

Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire January 17, 2023

Lyra Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire November 9, 2022

Lyra Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire November 8, 2022

Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire September 13, 2022

Lyra Therapeutics Advances Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients to Randomized Stage of Study

PR Newswire September 13, 2022

LYRA THERAPEUTICS announces additional data presentations FROM PHASE 2 LANTERN STUDY at the americal rhinologic society annual meeting

PR Newswire September 10, 2022

Lyra Therapeutics Announces First Patient Enrolled in Pivotal ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis Patients

PR Newswire September 8, 2022

Lyra Therapeutics to Present at the H.C. Wainwright AnnualGlobal Investment Conference 2022

PR Newswire September 6, 2022

Lyra Therapeutics to Present Additional LANTERN Phase 2 Study Results for LYR‑210 in Two Oral Presentations at ARS Annual Meeting

PR Newswire August 29, 2022

Lyra Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

PR Newswire August 9, 2022

Lyra Therapeutics to Present at the William Blair Biotech Focus Conference 2022

PR Newswire July 5, 2022

Lyra Therapeutics Announces Appointment of Richard Nieman, MD, as Chief Medical Officer

PR Newswire July 5, 2022

Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire June 17, 2022

Lyra Therapeutics to Present at Upcoming Investor Conferences

PR Newswire May 26, 2022

Lyra Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

PR Newswire May 10, 2022

Lyra Therapeutics to Present at Upcoming Investor Conferences

PR Newswire May 5, 2022

Lyra Therapeutics Presents Positive Data from LANTERN Phase 2 Study of LYR-210 for Treatment of Chronic Rhinosinusitis at COSM 2022

PR Newswire April 29, 2022